Abstract
Purpose To characterize retinal tears (RTs) and calculate the economic burden of RTs that present to the emergency department (ED) in the US.
Methods We used a large national ED database to retrospectively analyze RTs that presented to the ED from 2006 to 2019. Using extrapolation methods, national estimates of RT incidence, demographics, comorbidities, disposition, inpatient (IP) costs, and ED costs were calculated.
Results During the time period between 2006 and 2019, 15,841 patients presented to the ED with RT as the primary diagnosis. RT incidence was stable at 8.2 per million US population (95% Confidence Interval (CI): 5.3 - 21.0) in this time period. Most patients were males, Caucasian, paid with private insurance, and admitted to EDs in the Northeast. The most common comorbidities were hypertension (19%), a history of cataracts (15%), and diabetes (7.2%).
During this time period, RTs costs added up to more than $79 million and $33 million in the ED and IP settings, respectively. Mean per-patient ED and IP costs increased by 145% (p=0.0008) and 86% (p=0.0047), respectively.
Conclusion Despite the stable incidence of RTs, RTs place a significant economic burden to the healthcare system, which increases yearly. We recommend physicians and policy makers to work together to pass laws that could prevent the increasing healthcare costs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We only use de-identified data, which does not require IRB approval. This study was given ethical approval by the Health Care Utilization Project (the owner of this dataset).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: The authors declare no relevant financial support.
Conflict of Interest: None of the authors of this study have any conflict of interests or proprietary interests
Data Availability
The data can be bought from the following link:https://www.hcup-us.ahrq.gov/nedsoverview.jsp
